Member Info for Laura2022

From the RNS about biostatistics last month

Biostatistics is a NECESSARY component to the setup, conduct and reporting of a interventional clinical trial,

from Phase 1 through to Phase 4, REGARDLESS of the therapeutic area. This opens up a SIGNIFICANT market for the

Company, giving greater opportunity to scale

I've highlighted the words of particular emphasis and I think Trench also highlighted a similar point a few weeks ago

Says the person in GBP which has wasted £50mln in 10yrs nearly !!

And has has about 2 fund raises per year for 10-15yrs

Are you sure JJ

All I can see is 3 stable days at 0.9-95 and offerings more than the bid to sell plenty

Gluck

Expand our services and market reach, helping to accelerate conversion of new opportunities into contracts. From an operational standpoint, the role will provide operational governance and line-management of the technical team, ensuring efficient delivery of high-quality consultancy projects.

Dr Peter Sargent, CEO, commented: "We are delighted to welcome Mark to our team. We feel that his unique mix of technical and commercial experience spanning across modelling & simulation, data science and drug development, he will be a great addition to the Company".

Offering over 09.2p to sell

Think it moves soon

Look at ilovesushi posting history

He's an irritant

He forgot

1) PYC only raised in July

2) BOD wages lowest on AIM

Look at what he pumps !! Eg CPX which has done 2 HUGE placings in last 6mths

Jaari

1 why have you just arrived after 9yrs absence

2 why are you comparing FAB to a $900mlm company

3 why are you Thiopia of ADVFN

Look at this person's posting history says it all

He won't answer any of my questions either

Next shipment from Takob ready for November delivery

The Takob Mine, which is 100% financed, will provide the Company with a 12.25 percent royalty over all sales of non-ferrous concentrate and any other metals produced.

Thanks Ralph

Huge global market and PYC at forefront

06:51

Thanks trench

October 31, 2024 /EINPresswire.com/ -- The biosimulation market is projected to grow from $4.03 billion in 2023 to $4.57 billion in 2024, with a compound annual growth rate (CAGR) of 13.4%. This growth during the historical period can be attributed to the increasing complexity of diseases, the rise of in silico trials, reductions in drug development costs, and the rising prevalence of chronic diseases.

The ignorant trolls don't realise we saved £60k by getting rid of CC in May 2024, and this therefore pays for these recent appointments

AND

PYC have lowest BOD wages on entire AIM market

The bio simulation market is huge

Jaari

Go away

Senior Management Announcement

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the hiring this week of a new senior member of its team, Dr Mark Davies, as Head of Quantitative Pharmacology and Data Science.

Dr Mark Davies brings over 20 years' experience in drug development, both from the perspective of working within major pharmaceutical companies (such as AstraZeneca) as well as from within service businesses supporting biopharma companies worldwide

Thanks TP123

Thanks trench

October 31, 2024 /EINPresswire.com/ -- The biosimulation market is projected to grow from $4.03 billion in 2023 to $4.57 billion in 2024, with a compound annual growth rate (CAGR) of 13.4%. This growth during the historical period can be attributed to the increasing complexity of diseases, the rise of in silico trials, reductions in drug development costs, and the rising prevalence of chronic diseases.

Agree PP

Uncanny U turns and posts last 9mths make him totally untrustworthy

So....lets get this straight..you're lauding and referencing a CEO that did zero/nothing

Sums it up really

So what did Satu do that warrants aclaim?